$INDP

Indaptus Therapeutics, Inc.

Indaptus Therapeutics is a clinical biotechnology company developing systemically administered immunotherapies for cancer and viral infections. Its patented technology uses single strains of attenuated and killed, non-pathogenic Gram-negative bacteria intended to activate both innate and adaptive immune responses. Its lead product candidate, Decoy20, was evaluated in a Phase 1 study for advanced solid tumors, including a combination study with BeOne’s anti-PD-1 antibody, Tislelizumab. The company has discontinued enrollment in the combination study, has no participants remaining in it and has no current plans to initiate a new clinical trial. Indaptus has historically operated virtually, using consultants and advisors and contract research organizations for research and development. It funds operations primarily through public and private offerings of equity securities. Indaptus is headquartered in New York, NY.

1
2
1

No SEC Form 4 filings for $INDP in the last 30 days.

See all $INDP insider activity →
Low

Indaptus Therapeutics Reports $5.4 Million Nine-Month Loss and Updates Strategy

Indaptus Therapeutics reported a net loss of $5.4 million for the first nine months of 2026, down from $12.7 million a year earlier. Research and development expenses declined 83% to $1.1 million. The company has $30.6 million in cash and is exploring new research opportunities, including a neurotechnology device for sleep-related conditions. Proceeds from a private placement will fund working capital and R&D.

Indaptus Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Indaptus Therapeutics, Inc. (INDP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Indaptus Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update NEW YORK (November 13, 2026) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a biotechnology company dedicated to immunotherapy research, toda

Indaptus Therapeutics 3Q 2026: EPS ($0.01) — 10-Q Summary

Indaptus Therapeutics reported a 65% narrower net loss YoY for 3Q 2026, with expenses falling due to reduced clinical activity and payroll costs. R&D expenses dropped 82% to $271,204, while G&A expenses declined 24% to $864,663. The company discontinued further enrollment in its Decoy20 study and began a new research collaboration with Kunming University of Science and Technology.

INDP sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 4 news stories mentioning INDP (Indaptus Therapeutics, Inc.). Coverage has been balanced: 1 bullish, 2 neutral, and 1 bearish.

Recent INDP coverage spans financial news, corporate actions and earnings.

What's driving INDP

  • Lower losses and a sizable cash balance reduce near-term funding risk, but the update remains early-stage with no clinical or regulatory milestone.

    tradingview.com · Nov 13, 2026

  • The 8-K provides fresh capital-structure information (private placement proceeds and cash runway) and updated operating expense trajectory, which can shift near-term risk perception for the biotech.

    SEC EDGAR 8-K · Nov 13, 2026

  • Loss reduction and lower R&D spend suggest improving cost discipline, likely supporting modest upside.

    tradingview.com · Nov 13, 2026

  • The pause likely triggers sell pressure as investors reassess near‑term prospects.

    tradingview.com · Nov 13, 2026

  • The dilution from the new shares may exert downward pressure on the stock price.

    SEC EDGAR 8-K · Oct 20, 2026

AlphAI scores every news story that mentions INDP with an AI model for sentiment and relevance, and aggregates insider trades from Indaptus Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $INDP

Score

Indaptus Therapeutics Reports $5.4 Million Nine-Month Loss and Updates Strategy

Indaptus Therapeutics reported a net loss of $5.4 million for the first nine months of 2026, down from $12.7 million a year earlier. Research and development expenses declined 83% to $1.1 million. The company has $30.6 million in cash and is exploring new research opportunities, including a neurotechnology device for sleep-related conditions. Proceeds from a private placement will fund working capital and R&D.

$INDPMedEarnings

Indaptus Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Indaptus Therapeutics, Inc. (INDP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Indaptus Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update NEW YORK (November 13, 2026) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a biotechnology company dedicated to immunotherapy research, toda

Indaptus Therapeutics 3Q 2026: EPS ($0.01) — 10-Q Summary

Indaptus Therapeutics reported a 65% narrower net loss YoY for 3Q 2026, with expenses falling due to reduced clinical activity and payroll costs. R&D expenses dropped 82% to $271,204, while G&A expenses declined 24% to $864,663. The company discontinued further enrollment in its Decoy20 study and began a new research collaboration with Kunming University of Science and Technology.

$INDPMedOffering· 20.34M · completed

Indaptus Therapeutics, Inc. (INDP): The Company completed the Private Placement, having received the full purchase price from each of the Purchasers in accordance with the terms of the Purchase…

Indaptus Therapeutics, Inc. (INDP) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On October 16, 2026, the Company completed the Private Placement, having received the full purchase price from each of the Purchasers in accordance with the terms of the Purchase Agreement, as amended. In connection with the closing of the Private Placeme

$INDPMedOffering· $24M · priced

Indaptus Therapeutics, Inc. (INDP): Entry into a Material Definitive Agreement

Indaptus Therapeutics, Inc. (INDP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. As previously disclosed in the Current Report on Form 8-K filed by Indaptus Therapeutics, Inc. (the “ Company ”) with the Securities and Exchange Commission on September 9, 2026 (the “ Prior Form 8-K ”), on September 8, 2026,

Biotech Stocks Gain Ground: PDS Biotech, Clene, Indaptus Lead Movers

PDS Biotech (PDSB) announced a $22.55M PIPE financing for late-stage cancer drug development, shares up 50.64%. Avaí Bio (AVAI) completed cell bank testing, shares up 14.29%. Clene (CLNN) priced a $4M offering, shares up 25.25%. NurExone (NRX.V) partnered with NanoPass, shares up 8.06%. Cardiff Oncology (CRDF) settled a licensing dispute, shares up 4.58%. Indaptus (INDP) shares surged 16.88% without specific news.

$INDPMedOffering· $24M · proposed

Indaptus Therapeutics, Inc. (INDP): Entry into a Material Definitive Agreement

Indaptus Therapeutics, Inc. (INDP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On September 8, 2026, Indaptus Therapeutics, Inc. (the “ Company ”) entered into a Stock Purchase Agreement (the “ Purchase Agreement ”) with the purchasers party thereto (collectively, the “ Purchasers ”), pursuant to which

Related tickers